Matthew E. Korenberg is a seasoned finance executive with over 25 years of experience in the pharmaceutical and biotechnology industries. He began his career at Deloitte & Touche, where he honed his expertise in audit and advisory services for life sciences clients. Korenberg later advanced to senior roles at Pfizer Inc., including Director of Finance for Global Manufacturing and Supply, managing financial operations for a multibillion-dollar portfolio. His strategic acumen led him to Endo International plc, where he served as Vice President of Finance, overseeing mergers, acquisitions, and financial reporting during a period of significant growth. Throughout his career, Korenberg has played pivotal roles in transformative transactions, including the $1.6 billion acquisition of Auxilium Pharmaceuticals by Endo and the successful IPO and subsequent sale of Strongbridge Biopharma to Xeris Biopharma in 2022, where he served as Chief Financial Officer. His achievements include raising over $300 million in equity and debt financings, implementing robust financial controls, and navigating complex regulatory environments to drive shareholder value in dynamic biotech settings. As Chief Financial Officer at Palvella Therapeutics Inc., a clinical-stage biotechnology company developing therapies for debilitating rare diseases like epidermolysis bullosa, Korenberg leads all financial operations. He directs capital raising efforts, including a landmark $125 million Series B financing in 2023, financial planning, investor relations, and compliance. Under his leadership, Palvella has advanced its lead asset, PTX-025, into clinical trials while maintaining a strong balance sheet to support pipeline expansion.